Baxter International (NYSE:BAX) witnessed a selling pressure and the shares last traded with a loss of -0.04 points or -0.09% at $44.92. Investors jumped in to buy the shares on weakness. The net money flow till latest update was calculated at $2.57 million with an inflow of $12.62 million in upticks and an outflow of $10.05 million in downticks. Using the data, the up/down ratio is found to be 1.26. The share price has recorded 1.08% on a weekly basis.A block trade of $2.59 million in uptick and $0 million in downtick was also observed, resulting in an up/down ratio of 0. The net money flow of the block trade stood at a $2.59, signaling heavy buying.
The stock has recorded a 20-day Moving Average of 2.53% and the 50-Day Moving Average is 2.48%. The company shares have rallied 17.12% in the past 52 Weeks. On May 12, 2016 The shares registered one year high of $46.95 and one year low was seen on October 6, 2015 at $32.18. The 50-day moving average is $44.37 and the 200 day moving average is recorded at $40.36. S&P 500 has rallied 1.93% during the last 52-weeks.
Baxter International (NYSE:BAX): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $45.05 and $44.59 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $45.11. The buying momentum continued till the end and the stock did not give up its gains. It closed at $45.01, notching a gain of 0.11% for the day. The total traded volume was 2,810,468 . The stock had closed at $44.96 on the previous day.
Currently the company Insiders own 1.08% of Baxter International shares according to the proxy statements. Institutional Investors own 84.39% of Baxter International shares. During last six month period, the net percent change held by insiders has seen a change of -23.18%. On the companys insider trading activities, Almeida Jose E, CEO of Baxter International Inc, had purchased 11,691 shares on May 23, 2016. The total value of the transaction was $499,790. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.